Back
Corporate News
SMS Pharmaceuticals reports Rs 207 crore revenue, 6% growth, and approves Rs 50 crore loan
01-Aug-2026, 06:17
SMS Pharmaceuticals Limited (NSE: SMSPHARMA; BSE:532815) announced its unaudited financial results for the quarter ended June 30, 2026, reporting revenue from operations of Rs 207.0 crore, a 6% year-over-year increase driven by broad-based growth across high-value APIs. The company’s profit after tax increased 8% year-over-year to Rs 20.20 crore, while maintaining an EBITDA margin of 20%, and the board approved an infusion of up to Rs 50 crore as a loan into its subsidiary, SMS Peptides Private Limited, to establish a dedicated peptide R&D facility.
SMS Pharmaceuticals Limited (NSE: SMSPHARMA; BSE:532815) announced its unaudited financial results for the quarter ended June 30, 2026, reporting revenue from operations of Rs 207.0 crore, a 6% year-over-year increase driven by broad-based growth across high-value APIs. The company’s profit after tax increased 8% year-over-year to Rs 20.20 crore, while maintaining an EBITDA margin of 20%, and the board approved an infusion of up to Rs 50 crore as a loan into its subsidiary, SMS Peptides Private Limited, to establish a dedicated peptide R&D facility.